Signal, buried.
Thousands of trials, abstracts and filings land every month. The one move that changes your strategy is in there — you just can't surface it in time.
COMPETITIVE INTELLIGENCE · ONCOLOGY-ONLY
Oncology competitive intelligence, before the landscape moves.
Prognyx turns the noise of trials, readouts, deals and regulatory moves into continuous, sourced, decision-ready intelligence — mapped around your pipeline, not a database you have to mine.
3,000+ trials watched
72h move-to-brief
1 focus — oncology
[ 01 ] THE PROBLEM
The field moves faster than any team can track.
Tools, not answers.
A six-figure database hands you data to mine. A consulting project hands you a deck — once. Neither watches your back on a Tuesday afternoon.
Priced for giants.
Enterprise intelligence is built for big-pharma budgets. The biotech with the most riding on a single asset is the one left flying blind.
0
oncology trials in motion, watched to the primary record
0
from competitor move to a brief on your desk
1
therapeutic focus — oncology, and nothing else
[ 02 ] WHAT PROGNYX DOES
Oncology competitive intelligence, on continuous watch.
Not a portal you log into. Not a report you wait six weeks for. A standing intelligence function for your pipeline — reading every trial, readout, label and deal that touches your space, and telling you what it means and what to do.
- Continuous. The watch never stops between deliverables.
- Sourced. Every claim traces back to the primary record — NCT, label, abstract, filing.
- Decision-ready. The so-what and the now-what, not a data dump.
- Tailored. Scoped to your assets, mechanisms and indications.
COMPETITIVE BRIEF
LIVE WATCH
KRAS G12C — second-line NSCLC
Competitor readoutESMO 2026
Threat levelElevated
Window to act~6 weeks
78
A rival's confirmatory data lands before your filing. Here's the angle, the risk to your positioning, and the three moves on the table.
SOURCED · ClinicalTrials.gov · ESMO abstract · FDA label
[ 03 ] HOW IT WORKS
From noise
to a decision,
in four moves.
Define
We map your competitive set — targets, mechanisms, indications and the assets that can move your value.
SCOPEWatch
We track trials, congress readouts, regulatory actions, deals and publications — straight to the primary source.
MONITORSynthesize
We turn it into what it means for you and what to do next — sharp, sourced, no filler.
ANALYZEDecide
You get briefs your team actually reads and forwards — plus answers on demand when the field shifts.
ACTThe next move,
first.
Start with a sample→
[ 04 ] WHY PROGNYX
Not a database. Not a $150k deck. Your analyst.
Prognyx
Data platforms
Consulting
Continuous watch
Tailored to your pipeline
Decision-ready (the so-what)
Oncology-deep
Days, not weeks
Accessible to a single-asset biotech
We don't out-database the giants. We out-matter them — on the one question they can't answer for you: what do I do about this, on my molecule, this week?
[ 05 ] FROM THE WATCHTOWER
Oncology intelligence, in the open.
Sonesitatug vedotin won overall survival in CLARITY-Gastric01 and missed its PFS co-primary — and moved the…
AstraZeneca's 27 July release names the trial and describes the caveat precisely — the PFS co-primary showed a trend but did not reach statistical significance. The…
Read briefing →
Daraxonrasib's NDA is accepted with a National Priority Voucher — which puts an FDA decision in weeks, not…
Revolution Medicines' 22 July release confirms the FDA accepted the daraxonrasib NDA in previously treated metastatic pancreatic cancer, and that the asset sits in the…
Read briefing →
Ivonescimab's Western OS hazard ratio falls to 0.76 — Summit hasn't yet disclosed the number the FDA said it…
Summit's July 22 HARMONi update shows the Western overall-survival HR converging on the ITT 0.76 as follow-up doubles — but with no median, CI or p-value disclosed, the…
Read briefing →
AstraZeneca's NCT06764875 pits a rilvegostomig–Enhertu regimen against the pembrolizumab comparator in…
A three-arm, 840-patient Phase 3 — recruiting now, primary completion estimated April 2029 — tests AstraZeneca's largely owned rilvegostomig-plus-Enhertu combination…
Read briefing →
Elicio's KRAS vaccine missed its Phase 2 primary endpoint. It's staking a Phase 3 on the subgroup that worked.
ELI-002 7P failed disease-free survival in the AMPLIFY-7P intent-to-treat population — and Elicio is pressing into a larger, R0-enriched Phase 3 on a post-hoc result and…
Read briefing →
Spectrum Exits the Poziotinib Exon 20 Program: Four Trials Halted, Stated Reasons Explicitly Exclude Safety
Four terminated or suspended studies, zero Phase 3 enrollees, active FDA redesign talks: stated reasons across all Spectrum-sponsored poziotinib terminations explicitly…
Read briefing →[ 06 ] THE OFFER
See the next move first.
Tell us the one asset you'd want watched. We'll send back a sample competitive brief on it — sourced, sharp, no strings. If it's not the clearest read you've had on your space, you owe us nothing.
How Prognyx knows this
Every claim is built from primary sources only — and traces back to a document you can open. No opinion you can't check.
Who's behind it
Rali Filali — founder of Prognyx · M.D. candidate. Independent — no platform or bank behind the read. Every brief is audited against the primary record before it reaches you. Competitive analysis of public information — not medical or investment advice.
Retainers from $2,000/month — scoped to your pipeline, a fraction of a $100k+ enterprise platform. Or start with a one-off pilot brief ($1,500–3,000). What's included
ONCOLOGY COMPETITIVE INTELLIGENCE · PROGNYX